Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GPCRNASDAQ:MESONASDAQ:PRTANASDAQ:TVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGPCRStructure Therapeutics$21.79+0.1%$21.73$13.22▼$62.74$1.25B-1.69938,256 shs1.05 million shsMESOMesoblast$10.38-2.4%$11.19$5.78▼$22.00$1.33B2.5269,958 shs169,299 shsPRTAProthena$4.66+1.5%$8.70$4.32▼$25.42$250.83M0.11688,840 shs1.78 million shsTVTXTravere Therapeutics$15.52+3.3%$17.27$6.80▼$25.29$1.38B0.881.59 million shs1.56 million shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGPCRStructure Therapeutics+0.32%-11.24%-19.56%-3.11%-36.29%MESOMesoblast-2.17%-4.33%-13.86%-29.44%+39.52%PRTAProthena+1.53%-29.18%-45.18%-69.06%-77.61%TVTXTravere Therapeutics+3.60%-2.02%-26.62%-21.22%+109.16%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGPCRStructure Therapeutics1.9577 of 5 stars3.51.00.00.02.31.70.6MESOMesoblast1.5679 of 5 stars3.51.00.00.01.60.80.6PRTAProthena2.7948 of 5 stars4.21.00.00.02.01.71.3TVTXTravere Therapeutics2.5603 of 5 stars4.42.00.00.01.50.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGPCRStructure Therapeutics 3.00Buy$79.86266.49% UpsideMESOMesoblast 3.00Buy$18.0073.41% UpsidePRTAProthena 2.33Hold$31.50575.97% UpsideTVTXTravere Therapeutics 2.87Moderate Buy$31.79104.80% UpsideCurrent Analyst Ratings BreakdownLatest PRTA, GPCR, TVTX, and MESO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025PRTAProthenaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform5/27/2025PRTAProthenaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$110.00 ➝ $81.005/27/2025PRTAProthenaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$78.00 ➝ $29.005/27/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral5/27/2025PRTAProthenaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$6.005/27/2025PRTAProthenaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/27/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $14.005/27/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $18.005/16/2025TVTXTravere TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/16/2025TVTXTravere TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.005/13/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGPCRStructure TherapeuticsN/AN/AN/AN/A$9.77 per shareN/AMESOMesoblast$5.67M233.92N/AN/A$4.21 per share2.47PRTAProthena$137.94M1.82N/AN/A$10.46 per share0.45TVTXTravere Therapeutics$273.53M5.04N/AN/A$2.67 per share5.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGPCRStructure Therapeutics-$89.62M-$0.87N/AN/AN/AN/A-16.37%-15.68%8/7/2025 (Estimated)MESOMesoblast-$87.96MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)PRTAProthena-$147.03M-$2.08N/AN/AN/A-90.50%-22.67%-19.68%8/7/2025 (Estimated)TVTXTravere Therapeutics-$111.40M-$2.81N/AN/AN/A-137.90%-1,636.87%-55.95%7/30/2025 (Estimated)Latest PRTA, GPCR, TVTX, and MESO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025GPCRStructure Therapeutics-$0.24-$0.27-$0.03-$0.27N/AN/A5/8/2025Q1 2025PRTAProthena-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million5/1/2025Q1 2025TVTXTravere Therapeutics-$0.55-$0.47+$0.08-$0.47$77.44 million$81.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGPCRStructure TherapeuticsN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGPCRStructure TherapeuticsN/A27.6327.63MESOMesoblast0.211.181.18PRTAProthenaN/A11.5211.52TVTXTravere Therapeutics24.961.711.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGPCRStructure Therapeutics91.78%MESOMesoblast1.43%PRTAProthena97.08%TVTXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipGPCRStructure Therapeutics9.43%MESOMesoblast18.80%PRTAProthena9.20%TVTXTravere Therapeutics4.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGPCRStructure Therapeutics13657.34 million51.86 millionOptionableMESOMesoblast80127.78 million103.17 millionOptionablePRTAProthena13053.83 million38.64 millionOptionableTVTXTravere Therapeutics46088.81 million75.12 millionOptionablePRTA, GPCR, TVTX, and MESO HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 2 at 1:30 PM | globenewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to ConnectJune 2 at 10:00 AM | accessnewswire.comUniversal Beteiligungs und Servicegesellschaft mbH Buys New Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)June 2 at 4:41 AM | marketbeat.comPublic Employees Retirement System of Ohio Raises Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)June 2 at 4:25 AM | marketbeat.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Reach OutJune 1 at 10:00 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJune 1 at 10:00 AM | prnewswire.comAnalysts Set Travere Therapeutics, Inc. (NASDAQ:TVTX) PT at $31.79June 1 at 2:23 AM | americanbankingnews.comLevi & Korsinsky Launches Fraud Investigation on Behalf of Travere Therapeutics, Inc. (TVTX) ShareholdersMay 30, 2025 | accessnewswire.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 30, 2025 | marketbeat.comLost Money on Travere Therapeutics, Inc. (TVTX)? Possible Fraud - Contact Levi & Korsinsky TodayMay 29, 2025 | accessnewswire.comTravere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationMay 29, 2025 | accessnewswire.comTVTX Investor Notice: Levi & Korsinsky Investigates Travere Therapeutics, Inc. for Securities Law ViolationsMay 28, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to ConnectMay 28, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXMay 27, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Stockholders to Inquire about Securities InvestigationMay 27, 2025 | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the InvestigationMay 26, 2025 | accessnewswire.comTwo Sigma Investments LP Purchases 332,933 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)May 26, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Stock Position Raised by Man Group plcMay 26, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Bought by Millennium Management LLCMay 26, 2025 | marketbeat.comAmeriprise Financial Inc. Purchases 162,649 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)May 26, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Stockholders to Learn More About the InvestigationMay 25, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRTA, GPCR, TVTX, and MESO Company DescriptionsStructure Therapeutics NASDAQ:GPCR$21.79 +0.03 (+0.14%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$22.07 +0.28 (+1.28%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Mesoblast NASDAQ:MESO$10.38 -0.26 (-2.44%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$10.36 -0.02 (-0.19%) As of 06/2/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Prothena NASDAQ:PRTA$4.66 +0.07 (+1.53%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$4.59 -0.07 (-1.48%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.Travere Therapeutics NASDAQ:TVTX$15.52 +0.50 (+3.33%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$15.68 +0.16 (+1.03%) As of 06/2/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern 3 Stocks With 3% to 9% Yields Just Raised Dividends Again MarketBeat Week in Review – 05/26 - 05/30 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
